Better Health for All

Innate Pharma is dedicated to developing immunotherapies for cancer, aligning with the goal of improving health outcomes

. The company has a pipeline of products in various stages of clinical trials, including Lacutamab, Monalizumab, and IPH6501 , . Sanofi invested €15 million in Innate Pharma, showing confidence in their pipeline . The company received FDA Breakthrough Therapy Designation for Lacutamab . Innate Pharma collaborates with companies like AstraZeneca and Sanofi, potentially broadening access to treatments , . However, there is limited information on price accessibility, vulnerable population reach, and health equity programs , . The company received €6.8M from the French government for COVID-19 research . The company's focus on cancer treatment and innovation supports a positive score, but a lack of data on accessibility and equity limits a higher score. The company is investing in health innovation .

Fair Money & Economic Opportunity

Innate Pharma S.A. is a biotechnology company focused on research and development

, not a financial institution that lends, insures, moves, or stores money for consumers. The company's core business lies outside finance. Therefore, all KPIs related to fair money and economic opportunity for external customers, such as underserved client share, pricing fairness, exploitative fee exposure, data accessibility (customer finance data), fair lending compliance, wealth building outcomes for customers, financial literacy initiatives for customers, debt burden ratio, geographic inclusion (banking deserts), and product simplicity (financial products), are not applicable to its operations. While the company has internal employee inclusion initiatives and provides information on employee stock ownership plans and pension plans , these do not fall under the scope of financial inclusion or lending services for external customers as defined by the rubric.

Fair Pay & Worker Respect

Innate Pharma was certified as a "Great Place to Work" in 2019.

In the associated survey, 90% of employees reported being proud to work for the company, with an 86% participation rate. The company's employee departure rate for permanent contracts was 2.3% in 2017.

Honest & Fair Business

Innate Pharma's board has 87.5% independent directors.

The company adopted a Code of Business Conduct and Ethics on September 13, 2023, which covers legal compliance, including French and US laws, FCPA, MAR, and other international regulations, and addresses bribes and kickbacks. However, the policy's training is infrequent and lacks effectiveness metrics.

Kind to Animals

Innate Pharma conducts pre-clinical studies within a strict regulatory framework, adhering to Directive 2010/63/EU.

The company has an Ethical Committee on Animal Experimentation, affiliated with the National Ethics Committee since 2012, which approves all protocols considering scientific relevance and animal well-being. For studies assigned to external service providers, Innate Pharma ensures the same regulatory framework is adhered to. However, the company's antibody, IPH6501, was tested in mice and cynomolgus macaques, indicating the use of primates and other animals in testing. The company's 2015 CSR report mentions 4 animal testing accidents. The company's R&D activities are stated to have a limited impact on biodiversity, and its site is enclosed to protect the area's fauna, located near the Calanques national park. There is no evidence of specific non-animal methods being externally validated or covering a majority of internal safety assays, nor is there a percentage of R&D budget allocated to animal-free alternatives. The company does not publicly state a position on animal welfare legislation or engage in advocacy for higher standards.

Planet-Friendly Business

In 2017, the company's total Scope 1, 2, and 3 CO2 equivalent emissions from electricity consumption and business travel were 707.52 metric tons, representing a 15.78% decline from 840.14 metric tons in 2016.

The company's Code of Ethics states a policy to conduct business in an environmentally responsible way and minimize environmental impacts, with strict enforcement and channels for reporting violations. No environmental compliance violations are reported. The company's Prado site offices are rented in a new building certified BREEAM, but there is no information on other facilities. The company has waste sorting bins for paper and boxes, and a collection system for aluminum coffee capsules, but no specific waste diversion rate is provided. The main premises are located near the Calanques National Park, and green spaces are maintained according to regulations to protect the area's fauna, with the company site being enclosed.

Respect for Cultures & Communities

Innate Pharma's entire staff is based in Luminy, Marseille, meaning 100% of its workforce is located in that local community.

The company addresses the challenge of schooling for English-speaking families in Marseille, which is a limiting factor for international recruitment, indicating limited local language incorporation. Innate Pharma is located near the Calanques National Park and has taken actions to protect the area's fauna by enclosing its premises. The company has no reported cultural appropriation incidents and its operations do not inherently impact cultural contexts, making a specific cultural impact assessment protocol not applicable. While the company engages in numerous partnerships with academic institutions and a science and technology park association, these are not explicitly defined as formal partnerships with indigenous or local community groups in the context of the rubric. The company's business model does not involve FPIC processes or indigenous suppliers. It has standard grievance processes through employee representative institutions but no specific community-focused mechanisms or tracking of resolution times. The company does not have specific community representation on governance bodies, nor does it report on non-core revenue distribution to community funds. There is no explicit evidence for the percentage of revenue reinvested in local community development, cultural preservation investment, or charitable giving to cultural heritage organizations, as the company's total revenue for the relevant years is not provided in the articles.

Zero Waste & Sustainable Products

The company has implemented several waste reduction initiatives, including reducing paper consumption, using recycled paper, recycling office consumables, sorting waste, setting up a recycling system for plastic laboratory consumables in 2014, and establishing a collection system for aluminum coffee capsules.

For hazardous waste, the company states it complies with French environmental code and regulations for hazardous materials, genetically modified organisms, and radioactive products, entrusting biological and chemical waste to a specialist pick-up and recycling company. However, the quantity of laboratory waste sent to a special waste management center increased from 121,680 liters in 2015 to 204,520 liters in 2017. The company conducts annual reviews of its macro-risk map, which includes risk prevention and safeguarding, and initiated an energy audit in March 2015 with conclusions presented in October 2016. No facilities have zero waste certification. The company has not reported any waste disposal violations in the past three years. For suppliers, the company does not carry out CSR audits and only requires service providers to comply with applicable regulatory requirements and its operational and quality expectations.